Targeted Therapy vs Chemo for Lung Cancer?

It isn’t one against the other. The choice comes down to what molecular testing finds in the tumour. If the cancer carries a targetable mutation, like EGFR or ALK, targeted therapy usually works better and is easier to tolerate. If there’s no such mutation, chemotherapy is the answer. So the tumour’s genetics decide, not a general preference. Testing first, treatment second.

According to Dr. Sandeep Nayak, Surgical Oncologist in India, “Patients often ask me which is better, as if one always wins. But it depends entirely on the tumour. If molecular testing shows a mutation we have a drug for, targeted therapy is remarkable, high response, fewer side effects. If there’s no target, chemotherapy remains essential and effective. The mistake is choosing before testing. You can’t pick the right tool until you know what you’re dealing with.”

The two treatments work in fundamentally different ways, which is why testing matters so much.

• Targeted therapy : It blocks a specific fault driving the cancer, like a mutated EGFR gene. Precise, and mostly sparing of healthy cells.
• Chemotherapy : It attacks all rapidly dividing cells. Effective and broad, but it hits healthy fast growing cells too, which causes the familiar side effects.
• The mutation gate : Targeted therapy only works if the tumour has the matching mutation. No target, no benefit, which is why testing comes first.
• Chemo works regardless : Chemotherapy doesn’t need a mutation. It works across cancer types, which keeps it essential when there’s nothing to target.

Choosing correctly is central to good lung cancer treatment, and it starts with knowing the tumour’s molecular profile.

Here’s how the two line up side by side.

• When targeted wins : In a tumour with a matching mutation, targeted therapy often far outperforms chemotherapy, with much higher response and gentler side effects.
• When chemo is essential : No targetable mutation means chemotherapy is the right, effective choice. It remains a cornerstone of lung cancer treatment.
• Not always either or : Sometimes they’re combined or sequenced, chemo then targeted, or both together, depending on the tumour and stage.
• Testing decides : None of this works without molecular testing. It’s the step that turns a guess into a precise, personalised treatment plan.

All of this depends on the right cancer testing, which reveals the mutations that determine which treatment a patient actually needs.

Dr. Sandeep Nayak is a surgical oncologist with 24 years behind him and a fellowship in laparoscopic and robotic onco-surgery. He works within a multidisciplinary team where molecular testing guides systemic treatment, so the choice between targeted therapy and chemotherapy rests on the tumour’s actual biology rather than assumption. The approach insists on proper testing before treatment, since choosing blind is exactly what wastes a patient’s best option.

Modern lung cancer care lives or dies on getting this decision right. A tumour with an EGFR mutation treated with chemotherapy alone misses a far better option, while chemotherapy given for a mutation negative cancer is exactly correct. Reading the molecular profile and matching the treatment to it is what separates precise, effective care from a one size fits all approach. The testing is the key that unlocks the right plan.

References

1. Targeted therapy versus chemotherapy in EGFR-mutant lung cancer — National Library of Medicine
2. Neoadjuvant targeted therapy versus chemotherapy in NSCLC — National Library of Medicine

Disclaimer: This blog is for informational and educational purposes only and is not a substitute for professional medical advice or diagnosis.